GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.

Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr

The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY

Dr. Agarwals Eye Hospital posts standalone Q1 FY25 PAT higher at Rs. 14.11 Cr

Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024

Ajanta Pharma posts Q1 FY25 consolidated PAT at Rs. 245.77 Cr

Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024

Fredun Pharmaceuticals Q1 FY25 PAT drops QoQ to Rs. 4.12 Cr

Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024

Themis Medicare posts Q1 FY25 consolidated PAT higher at Rs. 24.68 Cr

Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024

Granules India posts Q1 FY25 consolidated PAT higher at Rs. 134.64 Cr

Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024

Pfizer Ltd. posts Q1 FY25 PAT at Rs. 150.71 Cr

Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024